Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
An electronic prescribing pattern cannot establish the original clinical indication or the advice provided at initiation.
A systematically designed intervention can be promising before its effectiveness has been established.
The proportion of toxicology-positive cases was larger than the proportion classified as acute intoxications.
Perceived safety is a valuable care-quality observation but is not the same outcome as prospectively measured complications.
Less behavioral response during capture does not by itself demonstrate prevention of capture-related death.
Infrequent repeat dosing can support a treatment hypothesis without directly measuring every seizure or proving complete control.
The trial compared combination ratios, so its results cannot isolate the effect of increasing either drug alone.
A favorable ranking for hypoxemia does not establish that a sedative is best for every complication.
Two successful inpatient courses do not establish the best method for treating zolpidem dependence.
A proposed care pathway should be described as expert guidance rather than as a trial-proven treatment algorithm.
Better comfort after a combined regimen cannot be assigned specifically to midazolam.
A pooled blood-pressure difference does not establish that one sedation regimen is safer on every important outcome.
Prolonged toxicant-induced seizures may respond differently from early seizures, but the proposed mechanism is supported more strongly by experiments than by controlled human evidence.
A hospital design intervention showed that a care-process result and a medication outcome are different claims.
A phase II trial found non-inferiority on a sleep questionnaire under a specified margin, rather than proof of identical treatments.
A biochemical study found that a cytosolic binding protein could influence measured CYP3A4-mediated diazepam oxidation.
A cardiac case included long-term alprazolam exposure but identified a recent AV-nodal blocker as the more likely precipitating factor.
A secondary pediatric analysis found that behavioral inhibition remained associated with preoperative anxiety after premedication.
A scoping review described potential ICU applications while finding important limits in the clinical evidence.
A laboratory formulation study compared mathematical manufacturing goals without establishing improved clinical absorption or anxiolysis.
A pediatric procedural case described a localized skin reaction temporally associated with remimazolam, without confirmatory allergy testing.
A neonatal audit’s high completion rate did not mean that less-invasive surfactant administration occurred without physiological events.
A pediatric ICU analysis associated even low benzodiazepine exposure with next-day delirium, without proving that every small dose causes delirium.
Street-tablet quantification demonstrated variable bromazolam content, while postmortem detections did not define a standalone lethal concentration.
A remimazolam–propofol trial found an early memory advantage without demonstrating a sustained difference in overall cognition at one month.
A randomized study found lower induction requirements after auditory stimulation, while its proposed neural mechanism remained uncertain.
A community study associated unexpected active-drug findings with subsequent self-reported behavior change, without demonstrating fewer overdoses.
A multicenter protocol proposed a comparison with midazolam in severe respiratory failure, but did not report that the planned intervention improved outcomes.
A population study found declining prescription overlap, while its registry definition and dispensing measures limited broader conclusions.
Preclinical experiments detected cardiac electrical effects that were not fully reflected by conventional QT measurements.